Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum.
Aida Kulo, Mariska Y Peeters, Karel Allegaert, Anne Smits, Jan de Hoon, Rene Verbesselt, Liesbeth Lewi, Marc van de Velde, Catherijne A J Knibbe
Index: Br. J. Clin. Pharmacol. 75(3) , 850-60, (2013)
Full Text: HTML
Abstract
A recent report on intravenous (i.v.) paracetamol pharmacokinetics (PK) showed a higher total clearance in women at delivery compared with non-pregnant women. To describe the paracetamol metabolic and elimination routes involved in this increase in clearance, we performed a population PK analysis in women at delivery and post-partum in which the different pathways were considered.Population PK parameters using non-linear mixed effect modelling were estimated in a two-period PK study in women to whom i.v. paracetamol (2 g loading dose followed by 1 g every 6 h up to 24 h) was administered immediately following Caesarean delivery and in a subgroup of the same women to whom single 2 g i.v.loading dose was administered 10-15 weeks post-partum.Population PK analysis was performed based on 255 plasma and 71 urine samples collected in 39 women at delivery and in eight of these 39 women 12 weeks post-partum. Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹). In contrast, there was no difference in clearance to paracetamol sulphate.The increased total paracetamol clearance at delivery is caused by a disproportional increase in glucuronidation clearance and a proportional increase in clearance of unchanged paracetamol and in oxidation clearance, of which the latter may potentially limit further dose increase in this patient group.© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Related Compounds
Related Articles:
Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen.
2001-06-15
[Blood 97(12) , 3846-50, (2001)]
2009-01-01
[Clin. Exp. Pharmacol. Physiol. 36(1) , 35-42, (2009)]
2012-06-01
[Bioanalysis 4(12) , 1429-43, (2012)]
2006-06-01
[Chem. Pharm. Bull. 54(6) , 891-6, (2006)]
Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice.
2000-01-01
[AAPS PharmSci 2(2) , E18, (2000)]